Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection.

Mariko HojoDaisuke AsaokaTsutomu TakedaYuji ShimadaKenshi MatsumotoKohei MatsumotoNoboru YatagaiYoichi AkazawaKumiko UedaHiroya UeyamaAkihito Nagahara

Published in: Therapeutic advances in gastroenterology (2020)

There were no significant differences in efficacy and safety between second-line therapies including VPZ or RPZ.

Keyphrases

helicobacter pylori infection
helicobacter pylori
double blind
open label
placebo controlled
stem cells
mesenchymal stem cells
cell therapy
endoscopic submucosal dissection